The E-SERIES Registry for Supralimus® Coronary Stent for the Treatment of Unselected Patients With Coronary Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01368627
Recruitment Status : Completed
First Posted : June 8, 2011
Last Update Posted : August 23, 2012
Cardiovascular Research Center, Brazil
Information provided by (Responsible Party):
Sahajanand Medical Technologies Pvt. Ltd.

Brief Summary:
E-SERIES Registry evaluate the procedural and clinical outcomes of the Supralimus® SES in the treatment of unselected, high risk patients having coronary Artery blockage in the real world clinical practice.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Device: Supralimus® Sirolimus-Eluting Coronary Stent Phase 4

Detailed Description:

E-SERIES Registry is Prospective, multinational (Asia, South America and Europe), non-randomized, post-marketing web-based registry.

For this Study Up to 100 clinical sites in Asia, South America and Europe. Patients "ALL COMERS" assigned for percutaneous coronary interventions who present with at least one angiographically documented coronary artery lesion suitable for percutaneous treatment with the Supralimus® SES.

All subjects who provided signed informed consent prior to procedure, and have at least one lesion in a major epicardial vessel or major branch (>2.25mm), and are suitable for percutaneous treatment including stenting procedure with the Supralimus® SES. There are no limit regarding the number of lesions and/or study stents to be used, and stenting technique will be left at the operator's discretion; however, it is recommended according to the BEST interventional practice according to the current guidelines.

All patients will undergo follow-up clinical evaluation at 1, 6, 12 and 24 months. Angiographic follow-up will be performed at 6 months in a subset of high risk lesions including bifurcations (first 100 lesions) and left main stem (first 100 lesions).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1274 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multinational Investigation of the Supralimus® Sirolimus-Eluting Stent for the Treatment of Unselected Patients With Coronary Lesions in the "Real- World" Clinical Practice
Study Start Date : January 2008
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Supralimus® Sirolimus-Eluting Coronary Stent Device: Supralimus® Sirolimus-Eluting Coronary Stent
Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
Other Name: Drug Eluting Stent (DES)

Primary Outcome Measures :
  1. MAJOR ADVERSE CARDIAC EVENTS (MACE) [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Rates of procedural success [ Time Frame: 24 month ]
  2. Rates of Major Adverse Cardiac Event (MACE) [ Time Frame: In-hospital, 30 days, 6 and 24 months ]
  3. Rates of target lesion revascularization (TLR) [ Time Frame: 6 and 12 months ]
  4. Rates of stent thrombosis (acute, sub-acute, late and very-late) [ Time Frame: Up to 24 months follow-up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. CLINICAL INCLUSION CRITERIA: Patients >18 years, clinical indication for elective or emergency percutaneous coronary intervention with stent implantation of at least one angiographically documented coronary artery lesion; agreement to undergo ALL study protocol follow-ups.
  2. ANGIOGRAPHIC INCLUSION CRITERIA: Diseased coronary vessels with at least one lesion with ≥50% diameter stenosis by visual estimation in a major epicardial vessel or a major branch (>2.25mm) with anatomy suitable for percutaneous treatment with the Supralimus SES.

Exclusion Criteria:

  1. CLINICAL EXCLUSION CRITERIA: Known illness with life expectancy <12 months; impossibility to comply with all protocol follow-ups.
  2. ANGIOGRAPHIC EXCLUSION CRITERIA: Anatomy unsuitable for percutaneous treatment with implantation of the Supralimus SES.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01368627

CIAS- Unimed Vitória
Vitória, Espírito Santo, Brazil, 29047-575
Centro de Cardiologia e Radiologia
Goiânia, Goiás, Brazil, 74823-320
Hospital Luxemburgo
Belo Horizonte, Minas Gerais, Brazil, 30380-090
Hospital Monte Sinai
Juiz de Fora, Minas Gerais, Brazil, 36025-550
Hospital Vita
Curitiba, Paraná, Brazil
Botucatu, Sao Paulo, Brazil
Hospital São Camilo
São Paulo, Brazil, 05022-001
Sponsors and Collaborators
Sahajanand Medical Technologies Pvt. Ltd.
Cardiovascular Research Center, Brazil
Principal Investigator: Alexandre Abizaid,, MD Instituto Dante Pazzanese de Cardiologia São Paulo, SP, Brazil

Responsible Party: Sahajanand Medical Technologies Pvt. Ltd. Identifier: NCT01368627     History of Changes
Other Study ID Numbers: Version 2.0
First Posted: June 8, 2011    Key Record Dates
Last Update Posted: August 23, 2012
Last Verified: August 2012

Keywords provided by Sahajanand Medical Technologies Pvt. Ltd.:
Coronary Artery Disease
Stent thrombosis
Coronary stents
Drug Eluting Stents(DES)

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs